Hold your nerve on this battered ASX share: expert

This healthcare stock has caused plenty of headaches for investors. But is it about to turn a corner?

| More on:
A healthcare worker wearing a white coat holds his fingers to his mouth looking worried as healthcare stocks like Cochlear crash today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One much-hyped ASX share has given little joy to investors over the last 12 months.

But The Montgomery Fund portfolio manager Joseph Kim has told holders of the healthcare stock to be patient, as the numbers still look pretty good.

Regenerative medicine maker AVITA Medical Inc (ASX: AVH) has seen its stock price plummet 40% in the past year.

"Price-agnostic index selling in October, a cash-burning business combined with a surprise capital raising in February that helped kill short-term price momentum, topped off by an uninspiring share price chart," Kim said on the Montgomery blog.

"It was relatively easy to paint a negative picture."

The shame of it all is that Avita shares were doing so well before the COVID-19 crash struck markets in February last year.

"COVID-19 and lockdowns in the US have stymied [its flagship product] RECELL roll-out just as it was gaining steam, as well as preventing recruitment for its various label extension plays in vitiligo, paediatric scalds and wound care."

Retesting the investment thesis for Avita

The sinking share price had Kim's team continually re-examining the investment worthiness of the US company.

One of the big reasons why The Montgomery Fund originally invested in Avita shares is the prospect of RECELL becoming the dominant player in the treatment of large burns in the US.

"While this remains some time away, there have been a couple of encouraging developments in June which we view as positive signposts along the journey," said Kim.

"In June, the company received FDA approval for expanded use of RECELL for pediatric patients. Included in the approval was expanded indication for treatment of full-thickness burns exceeding 50% total body surface area."

In the middle of last month, the company lifted its revenue forecast from a range of US$8.2 to US$8.6 million to a range of US$9.5 million to US$9.7 million.

"We understand the upgrade in guidance reflects both an increase in movement in the US – which unfortunately has led to greater burns incidents – as well normalisation of activity as the US 'exits' the pandemic given its advanced vaccination programs relative to other regions."

Remaining optimistic on Avita shares

Kim said the increased sales will assist Avita address two priorities.

"We anticipate improved sales should help the company fund its various label-extension opportunities in vitiligo and soft tissue, and alleviate some concern around the company's level of cash burn (which we note is an investment for future revenue growth)."

While not declaring a price target, Kim's team is holding onto Avita shares with high hopes.

"We remain optimistic the company will expand its addressable markets through both label extension and geographic expansion given the extensive evidence of real-world cases in its targeted indications, while also growing its current burns business for years to come."

Avita shares were down 2.39% on Monday, to trade at $5.32 in the afternoon.

Motley Fool contributor Tony Yoo owns shares of Avita Medical Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man and a woman sit in front of a laptop looking fascinated and captivated.
Healthcare Shares

Guess which ASX 200 company co-founders just sold $118 million in shares

This ASX 200 healthcare share is trading lower following the mammoth off-market block trade.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Mesoblast share price rips 12% on financial and operational updates

Mesoblast has set a price for its recently-approved flagship drug, which will go to market over the next few weeks.

Read more »

Six smiling health workers pose for a selfie.
Earnings Results

Medibank share price jumps 7% on strong half-year profit growth

Let's see how the health insurance giant performed during the half.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Earnings Results

This ASX healthcare stock is crashing 30% on half year results

Why is this stock crashing deep into the red today? Let's find out.

Read more »

Buy, hold and sell ratings written on signs on a wooden pole.
Healthcare Shares

CSL shares: Buy, sell or hold in 2025?

Three investment experts offer their view on the outlook for CSL shares.

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Earnings Results

Why has this ASX 200 healthcare stock crashed 24% in 2 days?

It has been a tough start to the week for this medical device company's shareholders.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

This little-known healthcare company is now the 17th-largest business in the ASX 200

This stock isn’t well-known, but it’s a market leader with significant potential.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why I think this ASX small-cap share is a buy at $1.18

After falling almost 17% over the past year, I see a lot of value at the current price.

Read more »